Evidence map›Paper›PMID 38967084›Full record

ArticleHistology and histopathology2025

Endometrial epithelial cell organoids as tools for studying the CD39 family of enzymes and for validating enzyme inhibitors.

Aitor Rodríguez-Martínez, Benjamín Torrejón-Escribano, Núria Eritja, Jonatan Dorca-Arévalo, Clara Gabaldón, Jean Sévigny, Xavier Matias-Guiu, Mireia Martín-Satué

Abstract read
PubMed Publisher
In one paragraph

Article in Histology and histopathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Aitor Rodríguez-MartínezPathology and Experimental Therapy Department, Faculty of Medicine and Health Sciences, Bellvitge Campus, Universitat de Barcelona, Barcelona, Spain.
Benjamín Torrejón-EscribanoPathology and Experimental Therapy Department, Faculty of Medicine and Health Sciences, Bellvitge Campus, Universitat de Barcelona, Barcelona, Spain.
Núria EritjaDepartament de Patologia i Genètica Molecular, Hospital Universitari Arnau de Vilanova, Lleida, Spain.
Jonatan Dorca-ArévaloPathology and Experimental Therapy Department, Faculty of Medicine and Health Sciences, Bellvitge Campus, Universitat de Barcelona, Barcelona, Spain.
Clara GabaldónPathology and Experimental Therapy Department, Faculty of Medicine and Health Sciences, Bellvitge Campus, Universitat de Barcelona, Barcelona, Spain.
Jean SévignyCentre de Recherche du CHU de Québec, Université Laval, Québec, Canada.
Xavier Matias-GuiuPathology and Experimental Therapy Department, Faculty of Medicine and Health Sciences, Bellvitge Campus, Universitat de Barcelona, Barcelona, Spain.
Mireia Martín-SatuéInstitut d'Investigació Biomèdica de Bellvitge (IDIBELL), Oncobell Program, CIBERONC, Barcelona, Spain.

Funding

Asociación Española Contra el Cáncer, GCTRA 18014MATICIBERONC CB16/12/00231Instituto de Salud Carlos III PI18/00541Ministerio de Ciencia e Innovación PID2021-126677NB-100Natural Sciences and Engineering Research Council RGPIN-2016-05867
6 · The paper itself

Abstract

Extracellular adenosine triphosphate (ATP) conducts a complex dynamic system of broadly represented cell signaling. Ectonucleotidases are the enzymes with nucleotide hydrolytic ability that regulate ATP levels in physiological and pathological conditions, thus playing a key role in the so-called purinergic signaling. Altered ectonucleotidase expression has been reported in cancer, and the ectonucleoside triphosphate diphosphohydrolase (NTPDase) family of enzymes, with its best-known form NTPDase1 (CD39), is targeted in cancer immunotherapy. The tandem of enzymes CD39-CD73 is responsible for the generation of immunosuppressive adenosine in the tumor microenvironment, and inhibition strategies are of great interest. Organoids have emerged as very convenient models for the study of tumors since they are three-dimensional cultures that retain many of the features of tissue. The present study aims to contribute to improving the methodology and the molecular tools needed for the study of ectonucleotidases in healthy and disease conditions. The study, performed in an endometrial cancer cell model, could be extended to other types of tumors and pathologies in which the purinergic system is involved. We generated organoids from endometrial cancer cells overexpressing NTPDase2 (CD39L1) and NTPDase3 (CD39L3) as fusion proteins with EGFP, and we performed functional assays by adapting

Indexed as

Antigens, CDApyraseEndometrial NeoplasmsEndometriumEnzyme InhibitorsEpithelial CellsOrganoidsCell Line, TumorFemaleHumansAntigens, CDApyraseCD39 antigenENTPD1 protein, humanEnzyme Inhibitors

Identifiers

PMID38967084

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.